Clinical

Articles

Amgen’s Biosimilar Trend Report finds that biosimilars have been introduced at a price that is generally 15% to 37% lower than the reference product.




Report: Biosimilars Have Saved the Health Care System $9.8 Billion

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

Shifting cancer patients to the physician setting for administration of cancer therapies could save insurers $1.28 billion.

Study: Insurers Pay More for Cancer Therapies Administered in Hospital Setting

Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations. 

Onco360 Chosen as a Specialty Pharmacy for Takeda’s Exkivity

This is the fourth approval for Jakafi, a JAK1/JAK2 inhibitor.

FDA Approves Jakafi for GVHD

Keytruda plus chemotherapy reduces the risk of death by 27% in patients with triple-negative breast cancer.

Merck Shares Significant Keytruda Breast Cancer Results

Tivdak is the first approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer.

FDA Approves Tivdak for Advanced Cervical Cancer

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 19, 2022.

FDA Accepts BMS Application for Opdivo/Relatimab Combination for Advanced Melanoma

The approval comes more than two months ahead of its PDUFA target date of December 4, 2021.


FDA Approves Cabometryx for Thyroid Cancer


Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations. This is the second approval for this mutation and the first oral therapy.



FDA Approves Exkivity, a Novel Oral Therapy for Lung Cancer


Real-world data show Erleada prolonged survival in both metastatic and non-metastatic castration-sensitive prostate cancer.